On the risk of delisting of ordinary shares of SAB Biotherapeutics, Inc. (SABS)

The International Trading System Limited (hereinafter — ITS) hereby informs on the information concerning delisting risk of ordinary shares of SAB Biotherapeutics, Inc. (ISIN US78397T2024, hereinafter — Shares) from The Nasdaq Stock Market LLC (hereinafter — Nasdaq).

Information on delisting risk of ordinary shares by Nasdaq

On November 6, 2024 SAB Biotherapeutics, Inc. (hereinafter – the Company) submitted Quarterly report on Form 10-Q to The United States Securities and Exchange Commission (hereinafter – SEC). According to the report, the Company has experienced net losses, negative cash flows from operations, anticipates that it will continue to generate losses for the foreseeable future and expects the losses to increase. As a result, the Company will require additional capital to fund operations in order to support long-term plans. These conditions led the Company’s management to raise substantial doubt about its ability to continue as a going concern for more than twelve months from the date of these financial statements. For more information, please refer to the report available on the SEC website.

Information regarding possible actions to be taken by ITS Ltd.

ITS Ltd. conducts regular monitoring of the relevant information disclosed by the Company. Delisting of the Company’s securities by Nasdaq will be considered to constitute a breach of the ITS Regulations on admitting financial instruments to trading and result in termination of trading in the Qualified Investments on ITS.